ArticleJournal of clinical medicine research2026
Bone Morphogenetic Protein-10 as a Predictor of Atrial Fibrillation Recurrence After Catheter Ablation: A Systematic Review and Meta-Analysis.
Article in Journal of clinical medicine research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Biomarkers of atrial cardiomyopathy may improve the prediction of recurrence of atrial fibrillation (AF) after catheter ablation. Bone morphogenetic protein-10 (BMP10) is an atrial-specific cardiomyocyte protein and a potential biomarker, but evidence is limited and not comprehensively synthesized. Methods: We performed a systematic review and meta-analysis of prospective cohort studies to evaluate the association between circulating BMP10 concentrations with AF recurrence after catheter ablation. Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were computed using a random-effects model. The primary analysis used unadjusted HRs per continuous BMP10 levels from all included studies. Secondary analyses were conducted based on the adjusted HRs of studies with continuous BMP10 and all studies, including one study that reported adjusted HRs based on quartiles. Results: Three studies were included. In the primary analysis without adjustment (n = 3), increased levels of BMP10 were significantly associated with recurrence of AF (pooled HR 1.53, 95% CI 1.13-2.07; P = 0.006), with moderate-to-high heterogeneity (I Conclusion: Elevated BMP10 levels are correlated with higher risk of AF recurrence following catheter ablation. Although the results are consistent across analyses, they should be interpreted with caution due to the small number of studies and methodological heterogeneity. BMP10 needs to be confirmed as a clinically applicable biomarker by larger prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.